February 15, 2018 – the company “Boehringer Ingelheim” and “NGOs Petrovax farm” successfully completed the next stage of localization of production of innovative of... Treatment of acute ischemic stroke has become more accessible for the population of Russia

February 15, 2018 – the company “Boehringer Ingelheim” and “NGOs Petrovax farm” successfully completed the next stage of localization of production of innovative of are called thrombolytics in the territory of the Russian Federation. The first batch of localized drug Actilyse® (alteplase) for the treatment of acute ischemic stroke enrolled in the medical institutions of the country.

Pavol Dobrocki, General Director of Boehringer Ingelheim in Russia: “We see that Russia needs to thrombolytic therapy while not fully satisfied. For example, in 2016 only about 12 000 stroke patients received treatment with alteplase. However, the projected number of patients who must undergoing thrombolysis (based on the annual number of 420 thousand cases of ischemic stroke in the Russian Federation), may be about 20-22, 000 per year. We aim to improve availability and together with our partner “NGOs Petrovax farm”, localize in Russia the production of two drugs, which are the “gold standard” thrombolytic therapy”.

Elena Arkhangelsk, President of the company “NPO Petrovax Pharm Project on transfer of production of biotech drugs is on a given schedule. The completion of the next phase of the project just-in-time secured accumulated experience in manufacturing high-tech products of the company “NPO Petrovax farm”. Through its implementation, the Russian doctors will be able to use in your practice innovative thrombolytic, now localized in Russian, for emergency care, and patients will receive timely therapy with quality drugs.”

Certificate preparation

Localization of Actilyse® (alteplase) is an important part of the joint project “Boehringer Ingelheim” and “NGOs Petrovax farm” on creation in Russia full-cycle production of drugs for the treatment of cardiovascular diseases. The project also includes the localization of innovative trombolitiki the Metaliz® (tenecteplase) for the treatment of myocardial infarction. Locally Packed product Metaliz® came on the market in August 2017.

The total for the Russian healthcare over two years (2017-2018) will be made more than 22,000 doses of the drug the Metaliz® and more than 67,000 doses of the drug Actilyse®.

Source of publication: “of NPO Petrovax farm”

No comments so far.

Be first to leave comment below.

Your email address will not be published. Required fields are marked *